Resonance® metallic stent in patients with ureterocutaneostomies

S. Proietti, M. Sofer, A. Giannantoni, L. Luciani, G. Taverna, G. Giusti

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the effectiveness and the safety of Resonance® stents in patients with ureterocutaneostomies (UCS). Materials and methods: We retrospectively enrolled all patients with UCS who presented with impaired ureteral drainage with traditional polymeric ureteral prosthesis. Preoperative and follow-up (1, 3, 6, 12 months) workup, after Resonance® placement, included: medical history, physical examination, serum laboratory tests, urinalysis, urine culture and urinary tract imaging by ultrasound, administration of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and an evaluation of patients’ satisfaction rate. In addition, the number of emergency department patient admissions and hospitalizations occurred 1 year before and after the stent Resonance® placement was noted. Results: Twenty-five renal units in 14 patients with UCS were included. Statistically significant improvements in creatinine serum levels, patients’ satisfaction rate, hydronephrosis and number of urinary tract infections (UTI) were found at 1-, 3-, 6-, and 12-month follow-up compared to baseline. Statistically significant differences in EORTC QLQ-C30 were detected only in Emotional, Social and Global QoL domains before and after Resonance® placement (p ® stents are effective and safe in patients with UCS refractory to polymeric ureteral prosthesis, reporting evidence for significant improvements in hydronephrosis rate, renal function, UTI, and patients’ satisfaction rate and QoL.

Original languageEnglish
Pages (from-to)207-212
Number of pages6
JournalInternational Urology and Nephrology
Volume48
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Stents
Patient Satisfaction
Hydronephrosis
Urinary Tract Infections
Prostheses and Implants
Quality of Life
Kidney
Urinalysis
Patient Admission
Serum
Urinary Tract
Research
Physical Examination
Hospital Emergency Service
Drainage
Ultrasonography
Creatinine
Neoplasms
Hospitalization
Urine

Keywords

  • Hydronephrosis
  • Infections
  • Quality of life
  • Resonance stent
  • Ureterocutaneostomy

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Resonance® metallic stent in patients with ureterocutaneostomies. / Proietti, S.; Sofer, M.; Giannantoni, A.; Luciani, L.; Taverna, G.; Giusti, G.

In: International Urology and Nephrology, Vol. 48, No. 2, 01.02.2016, p. 207-212.

Research output: Contribution to journalArticle

Proietti, S, Sofer, M, Giannantoni, A, Luciani, L, Taverna, G & Giusti, G 2016, 'Resonance® metallic stent in patients with ureterocutaneostomies', International Urology and Nephrology, vol. 48, no. 2, pp. 207-212. https://doi.org/10.1007/s11255-015-1174-y
Proietti, S. ; Sofer, M. ; Giannantoni, A. ; Luciani, L. ; Taverna, G. ; Giusti, G. / Resonance® metallic stent in patients with ureterocutaneostomies. In: International Urology and Nephrology. 2016 ; Vol. 48, No. 2. pp. 207-212.
@article{eed1db6f1de9454f9bf0c0d000a498a5,
title = "Resonance{\circledR} metallic stent in patients with ureterocutaneostomies",
abstract = "Purpose: To evaluate the effectiveness and the safety of Resonance{\circledR} stents in patients with ureterocutaneostomies (UCS). Materials and methods: We retrospectively enrolled all patients with UCS who presented with impaired ureteral drainage with traditional polymeric ureteral prosthesis. Preoperative and follow-up (1, 3, 6, 12 months) workup, after Resonance{\circledR} placement, included: medical history, physical examination, serum laboratory tests, urinalysis, urine culture and urinary tract imaging by ultrasound, administration of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and an evaluation of patients’ satisfaction rate. In addition, the number of emergency department patient admissions and hospitalizations occurred 1 year before and after the stent Resonance{\circledR} placement was noted. Results: Twenty-five renal units in 14 patients with UCS were included. Statistically significant improvements in creatinine serum levels, patients’ satisfaction rate, hydronephrosis and number of urinary tract infections (UTI) were found at 1-, 3-, 6-, and 12-month follow-up compared to baseline. Statistically significant differences in EORTC QLQ-C30 were detected only in Emotional, Social and Global QoL domains before and after Resonance{\circledR} placement (p {\circledR} stents are effective and safe in patients with UCS refractory to polymeric ureteral prosthesis, reporting evidence for significant improvements in hydronephrosis rate, renal function, UTI, and patients’ satisfaction rate and QoL.",
keywords = "Hydronephrosis, Infections, Quality of life, Resonance stent, Ureterocutaneostomy",
author = "S. Proietti and M. Sofer and A. Giannantoni and L. Luciani and G. Taverna and G. Giusti",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s11255-015-1174-y",
language = "English",
volume = "48",
pages = "207--212",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Resonance® metallic stent in patients with ureterocutaneostomies

AU - Proietti, S.

AU - Sofer, M.

AU - Giannantoni, A.

AU - Luciani, L.

AU - Taverna, G.

AU - Giusti, G.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Purpose: To evaluate the effectiveness and the safety of Resonance® stents in patients with ureterocutaneostomies (UCS). Materials and methods: We retrospectively enrolled all patients with UCS who presented with impaired ureteral drainage with traditional polymeric ureteral prosthesis. Preoperative and follow-up (1, 3, 6, 12 months) workup, after Resonance® placement, included: medical history, physical examination, serum laboratory tests, urinalysis, urine culture and urinary tract imaging by ultrasound, administration of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and an evaluation of patients’ satisfaction rate. In addition, the number of emergency department patient admissions and hospitalizations occurred 1 year before and after the stent Resonance® placement was noted. Results: Twenty-five renal units in 14 patients with UCS were included. Statistically significant improvements in creatinine serum levels, patients’ satisfaction rate, hydronephrosis and number of urinary tract infections (UTI) were found at 1-, 3-, 6-, and 12-month follow-up compared to baseline. Statistically significant differences in EORTC QLQ-C30 were detected only in Emotional, Social and Global QoL domains before and after Resonance® placement (p ® stents are effective and safe in patients with UCS refractory to polymeric ureteral prosthesis, reporting evidence for significant improvements in hydronephrosis rate, renal function, UTI, and patients’ satisfaction rate and QoL.

AB - Purpose: To evaluate the effectiveness and the safety of Resonance® stents in patients with ureterocutaneostomies (UCS). Materials and methods: We retrospectively enrolled all patients with UCS who presented with impaired ureteral drainage with traditional polymeric ureteral prosthesis. Preoperative and follow-up (1, 3, 6, 12 months) workup, after Resonance® placement, included: medical history, physical examination, serum laboratory tests, urinalysis, urine culture and urinary tract imaging by ultrasound, administration of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and an evaluation of patients’ satisfaction rate. In addition, the number of emergency department patient admissions and hospitalizations occurred 1 year before and after the stent Resonance® placement was noted. Results: Twenty-five renal units in 14 patients with UCS were included. Statistically significant improvements in creatinine serum levels, patients’ satisfaction rate, hydronephrosis and number of urinary tract infections (UTI) were found at 1-, 3-, 6-, and 12-month follow-up compared to baseline. Statistically significant differences in EORTC QLQ-C30 were detected only in Emotional, Social and Global QoL domains before and after Resonance® placement (p ® stents are effective and safe in patients with UCS refractory to polymeric ureteral prosthesis, reporting evidence for significant improvements in hydronephrosis rate, renal function, UTI, and patients’ satisfaction rate and QoL.

KW - Hydronephrosis

KW - Infections

KW - Quality of life

KW - Resonance stent

KW - Ureterocutaneostomy

UR - http://www.scopus.com/inward/record.url?scp=84955703858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955703858&partnerID=8YFLogxK

U2 - 10.1007/s11255-015-1174-y

DO - 10.1007/s11255-015-1174-y

M3 - Article

AN - SCOPUS:84955703858

VL - 48

SP - 207

EP - 212

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 2

ER -